The monoclonal anti-IL-9 antibody, given at a dose of 100 μg before allergen exposure, did not significantly reduce allergen-induced airway eosinophilia, but consistently reduced bone marrow eosinophilia, by a reduction of newly produced (BrdU+) and mature bone marrow eosinophils. This evidence concerns the gene IL9 and Increased total eosinophil count.